SG11202009341TA - C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof - Google Patents

C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof

Info

Publication number
SG11202009341TA
SG11202009341TA SG11202009341TA SG11202009341TA SG11202009341TA SG 11202009341T A SG11202009341T A SG 11202009341TA SG 11202009341T A SG11202009341T A SG 11202009341TA SG 11202009341T A SG11202009341T A SG 11202009341TA SG 11202009341T A SG11202009341T A SG 11202009341TA
Authority
SG
Singapore
Prior art keywords
same
pharmaceutical compositions
terminal cdnf
cdnf fragments
fragments
Prior art date
Application number
SG11202009341TA
Other languages
English (en)
Inventor
Mart Saarma
Mikko Airavaara
Merja Voutilainen
Li Ying Yu
Maria Lindahl
Original Assignee
Helsingin Yliopisto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsingin Yliopisto filed Critical Helsingin Yliopisto
Publication of SG11202009341TA publication Critical patent/SG11202009341TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
SG11202009341TA 2018-03-29 2019-03-29 C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof SG11202009341TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20185304 2018-03-29
PCT/FI2019/050258 WO2019185994A1 (en) 2018-03-29 2019-03-29 C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof

Publications (1)

Publication Number Publication Date
SG11202009341TA true SG11202009341TA (en) 2020-10-29

Family

ID=66103015

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009341TA SG11202009341TA (en) 2018-03-29 2019-03-29 C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof

Country Status (14)

Country Link
US (1) US12479895B2 (de)
EP (2) EP4678236A3 (de)
JP (2) JP2021519578A (de)
KR (1) KR20200138798A (de)
CN (1) CN112616315A (de)
AU (1) AU2019244323A1 (de)
BR (1) BR112020019696A2 (de)
CA (1) CA3094236A1 (de)
IL (1) IL277632A (de)
MX (1) MX2020010301A (de)
RU (1) RU2020131433A (de)
SG (1) SG11202009341TA (de)
TW (1) TW202003015A (de)
WO (1) WO2019185994A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202202898D0 (en) * 2022-03-02 2022-04-13 Babraham Inst Novel use
KR20240095008A (ko) * 2022-11-22 2024-06-25 경북대학교 산학협력단 신경염증성 질환 치료효과를 나타내는 신규 펩타이드 및 이의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
ATE140966T1 (de) 1990-09-25 1996-08-15 Genentech Inc Neuer neurotropischer faktor
US20020132978A1 (en) * 2000-03-21 2002-09-19 Hans-Peter Gerber VEGF-modulated genes and methods employing them
WO2002074956A2 (en) * 2001-03-20 2002-09-26 Prescient Neuropharma Inc. Dopaminergic neuronal survival-promoting factors and uses thereof
CA2441327A1 (en) 2001-03-30 2002-10-10 Geneprot, Inc. Human arginine-rich protein-related compositions
WO2006020580A2 (en) 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
AU2005339101B2 (en) 2005-12-14 2013-01-10 Herantis Pharma Plc. Novel neurotrophic factor protein and uses thereof
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
EA201400002A1 (ru) * 2011-06-09 2014-08-29 Юниверсити Оф Майами Способы лечения заболеваний сетчатки
FI20115870A0 (fi) * 2011-09-05 2011-09-05 Urmas Arumaee Neuroprotektiiviset soluihin tunkeutuvat peptidit
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
US20170274048A1 (en) 2014-03-28 2017-09-28 Buck Institute For Research On Aging Methods and compositions for modulating the imune system
US20170157243A1 (en) * 2014-06-24 2017-06-08 University Of Massachusetts MANF as a Regulator of Immune System Function
US20170252403A1 (en) * 2014-10-06 2017-09-07 Amarantus Bioscience Holdings, Inc. Methods and compositions for treating retinal disorders
WO2018202957A1 (en) * 2017-05-04 2018-11-08 Helsingin Yliopisto C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof
CN107149673A (zh) * 2017-05-18 2017-09-12 山东大学 神经营养因子cdnf在制备缺血性脑血管疾病药物中的应用

Also Published As

Publication number Publication date
CN112616315A (zh) 2021-04-06
JP2021519578A (ja) 2021-08-12
MX2020010301A (es) 2020-10-20
EP3774858B1 (de) 2025-07-30
US20210009645A1 (en) 2021-01-14
RU2020131433A (ru) 2022-05-04
CA3094236A1 (en) 2019-10-03
JP2024056762A (ja) 2024-04-23
AU2019244323A1 (en) 2020-10-08
EP4678236A2 (de) 2026-01-14
EP3774858A1 (de) 2021-02-17
WO2019185994A1 (en) 2019-10-03
BR112020019696A2 (pt) 2021-01-05
IL277632A (en) 2020-11-30
TW202003015A (zh) 2020-01-16
KR20200138798A (ko) 2020-12-10
EP4678236A3 (de) 2026-04-08
US12479895B2 (en) 2025-11-25
EP3774858C0 (de) 2025-07-30

Similar Documents

Publication Publication Date Title
IL283754A (en) Anti-claudin antibodies, preparations containing them and their uses
IL279015A (en) Anti-interleukin-17A antibody, its pharmaceutical preparation and its use
IL276169A (en) Peptide YY pharmacological formulations, compositions and methods
SG11202104687SA (en) Ret inhibitors, pharmaceutical compositions and uses thereof
IL268588A (en) Anti-gprc5d antibodies, compositions comprising same and uses thereof
SG11202104686QA (en) Ret inhibitors, pharmaceutical compositions and uses thereof
IL274297A (en) Pyrazolo-piperidine-converted indole-2-carboxamides, preparations containing them and their uses
EP3597735A4 (de) Ctla4-antikörper, pharmazeutische zusammensetzung und verwendung davon
EP3347472A4 (de) Zusammensetzungen mit cyp76ad1-clade-polypeptiden und verwendungen davon
EP3706741A4 (de) Pharmazeutische zusammensetzung und verwendung davon
IL266526A (en) Recombinant virus, preparations containing it and its uses
EP3697411A4 (de) Neuartige pharmazeutische zusammensetzung und verwendung davon
EP3642219A4 (de) Peptidzusammensetzungen und zugehörige verfahren
SG11202101435XA (en) ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF
ZA202006541B (en) Pharmaceutical composition comprising brexpiprazole
ZA202008034B (en) Ivosidenib forms and pharmaceutical compositions
IL277632A (en) CDNF fragments from the carboxyl end, pharmaceutical compositions containing them and their uses
IL270917A (en) Recombinant ROBO2 proteins, preparations, methods and their use
IL273725A (en) Peptides from Apanniadam10, preparations containing them and their uses
EP3399990A4 (de) Therapeutische zusammensetzungen mit peptiden und verwendungen davon
IL268971B1 (en) A polypeptide, a segment of a polypeptide, its derivation and their applications
EP3647325A4 (de) Pharmazeutische zusammensetzung mit pcsk-9-antikörper und verwendung davon
IL279707A (en) A pharmaceutical preparation that includes a polypeptide
GB2579240B (en) New processes, compositions and medical uses
EP3595696A4 (de) Immunogene peptidzusammensetzung